269 related articles for article (PubMed ID: 3974202)
1. Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation.
Brandwein SR; Sipe JD; Skinner M; Cohen AS
Lab Invest; 1985 Mar; 52(3):319-25. PubMed ID: 3974202
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E1 inhibition of experimental amyloidosis in CBA/J mice.
Brandwein SR; Sipe JD; Skinner M; Cohen AS
J Rheumatol; 1985 Jun; 12(3):418-26. PubMed ID: 4045840
[TBL] [Abstract][Full Text] [Related]
3. Colchicine in acute inflammation: stimulation of production of interleukin-1 and modulation of the acute phase serum amyloid A protein response.
Brandwein SR; Sipe JD; Tatsuta E; Skinner M; Cohen AS
J Rheumatol; 1984 Oct; 11(5):597-601. PubMed ID: 6334740
[TBL] [Abstract][Full Text] [Related]
4. FK506 inhibits murine AA amyloidosis: possible involvement of T cells in amyloidogenesis.
Ueda M; Ando Y; Nakamura M; Yamashita T; Himeno S; Kim J; Sun X; Saito S; Tateishi T; Bergström J; Uchino M
J Rheumatol; 2006 Nov; 33(11):2260-70. PubMed ID: 16981291
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of amyloid deposition. II. The effects of dimethylsulfoxide and colchicine therapy.
Kisilevsky R; Boudreau L; Foster D
Lab Invest; 1983 Jan; 48(1):60-7. PubMed ID: 6823092
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the amyloid SAA 3 gene in liver and peritoneal macrophages of mice undergoing dissimilar inflammatory episodes.
Rokita H; Shirahama T; Cohen AS; Meek RL; Benditt EP; Sipe JD
J Immunol; 1987 Dec; 139(11):3849-53. PubMed ID: 3680951
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis.
Kluve-Beckerman B; Hardwick J; Du L; Benson MD; Monia BP; Watt A; Crooke RM; Mullick A
Amyloid; 2011 Sep; 18(3):136-46. PubMed ID: 21830877
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis.
Mihara M; Shiina M; Nishimoto N; Yoshizaki K; Kishimoto T; Akamatsu K
J Rheumatol; 2004 Jun; 31(6):1132-8. PubMed ID: 15170926
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the major circulating precursors of proteins deposited in secondary amyloidosis by a recombinant mouse interleukin-1 receptor antagonist.
Grehan S; Herbert J; Whitehead AS
Eur J Immunol; 1997 Oct; 27(10):2593-9. PubMed ID: 9368615
[TBL] [Abstract][Full Text] [Related]
10. Experimental AA amyloidosis in mice is inhibited by treatment with triptolide, a purified traditional Chinese medicine.
Cui D; Hoshii Y; Kawano H; Sugiyama S; Gondo T; Liu Y; Ishihara T
Int Immunopharmacol; 2007 Sep; 7(9):1232-40. PubMed ID: 17630202
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy.
Kisilevsky R; Boudreau L
Lab Invest; 1983 Jan; 48(1):53-9. PubMed ID: 6823091
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin: its potential significance in murine AA amyloidogenesis.
Chronopoulos S; Lembo P; Alizadeh-Khiavi K; Ali-Khan Z
J Pathol; 1992 Jun; 167(2):249-59. PubMed ID: 1321903
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the second phase of amyloidogenesis in a mouse model by a single-dose colchicine regimen.
Shtrasburg S; Pras M; Gal R; Salai M; Livneh A
J Lab Clin Med; 2001 Aug; 138(2):107-11. PubMed ID: 11477377
[TBL] [Abstract][Full Text] [Related]
14. The effect of a liver protein synthesis inhibitor on plasma SAA levels in a model of accelerated amyloid deposition.
Kisilevsky R; Benson MD; Axelrad MA; Boudreau L
Lab Invest; 1979 Sep; 41(3):206-10. PubMed ID: 470340
[TBL] [Abstract][Full Text] [Related]
15. Rapid induction of experimental AA amyloidosis in mink by intravenous injection of amyloid enhancing factor.
Sørby R; Espenes A; Landsverk T; Westermark G
Amyloid; 2008 Mar; 15(1):20-8. PubMed ID: 18266118
[TBL] [Abstract][Full Text] [Related]
16. Further characterization of amyloid-enhancing factor.
Axelrad MA; Kisilevsky R; Willmer J; Chen SJ; Skinner M
Lab Invest; 1982 Aug; 47(2):139-46. PubMed ID: 7109539
[TBL] [Abstract][Full Text] [Related]
17. Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice.
Sugumaran G; Elliott-Bryant R; Phung N; Vitseva O; Kuberan B; Lech M
Scand J Immunol; 2004 Dec; 60(6):574-83. PubMed ID: 15584968
[TBL] [Abstract][Full Text] [Related]
18. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study.
Snow AD; Kisilevsky R
Lab Invest; 1985 Jul; 53(1):37-44. PubMed ID: 2409350
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate inhibits reactive amyloidosis in mice.
Murai T; Yamada T; Miida T; Arai K; Endo N; Hanyu T
Arthritis Rheum; 2002 Jun; 46(6):1683-8. PubMed ID: 12115201
[TBL] [Abstract][Full Text] [Related]
20. Are elevated serum amyloid A levels and amyloid-enhancing factor sufficient to induce inflammation-associated amyloid deposition?
Kisilevsky R; Tan R; Subrahmanyan L; Snow A
Appl Pathol; 1984; 2(6):308-15. PubMed ID: 6400464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
